Establishment of a Hairy Cell Leukemia Variant Cell Line, HCLv-07

Sasaki, Makoto; Aritaka, Nanae; Tsukune, Yutaka; Kawahara, Shimpei; Masuda, Azuchi; Tsutsui, Miyuki; Kanemitsu, Naoko; Sugimoto, Koichi

doi:10.1159/000210064

Cited by 4 publications

(7 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Using 191 hematologic cell lines, there was no correlation between Myf6 and either CD25, CD134, TRAP, or Annexin 1a. There are no cell lines resembling classic HCL to the extent that they express BRAF V600E, although there are several resembling HCLv [36,37]. None of the 191 hematologic cell lines examined were HCL or HCLv-like.…”

Section: Expression Of Myf6 In Ighv4-34+ Hcl and Investigation Of Thmentioning

confidence: 96%

Expression of the muscle-associated gene MYF6 in hairy cell leukemia

et al. 2020

View full text Add to dashboard Cite

Hairy cell leukemia (HCL) is a purine analog-responsive B-cell malignancy containing the BRAF V600E mutation, expressing CD22, CD11c, CD103, tartrate resistant acid phosphatase (TRAP) CD25, CD123, and annexin 1A. BRAF V600E and the latter 4 markers are usually absent in the more aggressive and chemoresistant variant HCLv. To evaluate differences between HCL and HCLv, expression microarrays comparing HCL with HCLv were performed for 24694 genes using 47323 probes. Microarray data from 35 HCL and 27 HCLv purified samples showed the greatest HCL-HCLv difference in the muscle-associated gene MYF6, expressed by its 2 probes 18.5-and 10.8-fold higher in HCL than HCLv (p<0.0001). By real-time quantitative PCR (RQ-PCR), 100% of 152 classic HCL samples were MYF6positive, vs 5 (6%) of 90 blood donors. MYF6-expression was also detected in 18 (35%) of 51 with HCLv, 11 (92%) of 12 with HCL expressing unmutated IGHV4-34, 35 (73%) of 48 with chronic lymphocytic leukemia (CLL), and 1 (8%) of 12 with mantle cell lymphoma. Hypomethylation status of MYF6 supported expression in HCL more than HCLv. Posttreatment blood samples becoming negative by flow cytometry remained MYF6+ by RQ-PCR in 42 (48%) of 87 HCL patients, and MYF6 RQ-PCR could detect 1 HCL in 10 5 normal cells. MYF6, universally expressed in HCL and in most CLL samples, may be a useful biomarker for these leukemias. Further studies are underway to determine the role of MYF6 in HCL.

show abstract

Section: Expression Of Myf6 In Ighv4-34+ Hcl and Investigation Of Thmentioning

confidence: 96%

Expression of the muscle-associated gene MYF6 in hairy cell leukemia

et al. 2020

View full text Add to dashboard Cite

show abstract

“…These include Hair-M, 1 HCLL-7876, 2 EH, 3 Eskol, 4 HC-1 (ref. 5) and HCLv-07, 6 examined to date for 'tumor'-associated CD20 phosphorylation, 7 interferon-a oncogene regulation, 8 CD11c gene expression 9 and HCL cell adhesion and migration. 10 Here we have assessed these HCL cell lines further by examining the phenotype in more detail, by comparing B-cell receptor (BCR) function and by evaluating the BRAF mutation.…”

mentioning

confidence: 99%

“…Of these cell lines, HCLv-07 is known to be derived from HCLv. 6 Under the WHO (World Health Organization) (2008) guidelines, HCL immunophenotype includes bright CD11c expression with CD103, CD25, CD123 and Annexin A1 (ANXA1) coexpression. 16 ANXA1 is regarded as the most specific tumor marker for HCL, as it is absent on other B-cell lymphomas [16][17][18] and is negative in HCLv to provide a highly relevant marker to segregate these two forms of disease.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Hairy cell leukemia cell lines expressing annexin A1 and displaying B-cell receptor signals characteristic of primary tumor cells lack the signature BRAF mutation to reveal unrepresentative origins

et al. 2012

View full text Add to dashboard Cite

“…Patients with HCV-JV possess splenomegaly without peripheral lymphadenopathy. Nonetheless, in comparison to HCL-C, but just like HCL-V, HCL-JV patients generally demonstrate leukocytosis and a conveniently aspirable bone marrow [11] . HCL-JV cells have an abundant pale cytoplasm with lengthy microvilli, round hyperchromatic nuclei, inconspicuous nucleoli and seldom consist of ribosome-lamella facilities [10] .…”

Section: Discussionmentioning

confidence: 97%

Management Approaches to Hairy Cell Leukemia : Overview

Al-Haddad¹,

Alsalim²,

Aljarrash³

2018

Egyptian Journal of Hospital Medicine

View full text Add to dashboard Cite

Hairy cell leukemia is a rare disease comprising about 2% of lymphoid neoplasms. In this review, the biology, diagnostic criteria, and current therapeutic options in HCL-V and HCL-JV are presented. We conducted a database; PubMed and Embase comprehensive search up to December 2017, we search a relevant trail to our concern topic (hairy cell leukemia). HCL-V is a distinct clinico-pathological entity. However, differentiating HCL-V from classical HCL and splenic marginal zone lymphoma (SMZL), which are both connected with noticeable splenomegaly and circulating neoplastic cells with 'hairy' projections remain a problem. Patients with HCL-V are usually older, splenomegaly is less typical and leucopenia with granulocytopenia and monocytopenia are generally not seen. Bone marrow is usually easily aspirable, hypercellular with mild myelofibrosis.

show abstract

Establishment of a Hairy Cell Leukemia Variant Cell Line, HCLv-07

Cited by 4 publications

References 27 publications

Expression of the muscle-associated gene MYF6 in hairy cell leukemia

Expression of the muscle-associated gene MYF6 in hairy cell leukemia

Hairy cell leukemia cell lines expressing annexin A1 and displaying B-cell receptor signals characteristic of primary tumor cells lack the signature BRAF mutation to reveal unrepresentative origins

Management Approaches to Hairy Cell Leukemia : Overview

Contact Info

Product

Resources

About